KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Net Income towards Common Stockholders: 2011-2024

Historic Net Income towards Common Stockholders for Travere Therapeutics (TVTX) over the last 14 years, with Dec 2024 value amounting to -$915,000.

  • Travere Therapeutics' Net Income towards Common Stockholders rose 25806.00% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.3 million, marking a year-over-year decrease of 1014.35%. This contributed to the annual value of -$915,000 for FY2024, which is 100.35% down from last year.
  • Per Travere Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$915,000 for FY2024, which was down 100.35% from $264.9 million recorded in FY2023.
  • Travere Therapeutics' Net Income towards Common Stockholders' 5-year high stood at $264.9 million during FY2023, with a 5-year trough of -$169.4 million in FY2020.
  • Its 3-year average for Net Income towards Common Stockholders is $105.7 million, with a median of $53.0 million in 2022.
  • Per our database at Business Quant, Travere Therapeutics' Net Income towards Common Stockholders skyrocketed by 400.01% in 2023 and then crashed by 100.35% in 2024.
  • Travere Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$169.4 million in 2020, then surged by 121.96% to $37.2 million in 2021, then spiked by 42.43% to $53.0 million in 2022, then surged by 400.01% to $264.9 million in 2023, then plummeted by 100.35% to -$915,000 in 2024.